Itopride in Functional Dyspepsia:a Dose Finding Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00272103|
Recruitment Status : Completed
First Posted : January 4, 2006
Last Update Posted : May 4, 2006
This study aims to determine the efficacy and optimal dose of the prokinetic itopride for the treatment of patients with functional dyspepsia.
The study will test in patients with functional dyspepsia the hypothesis that itopride is superior to placebo with regard to the improvement of symptoms.
|Condition or disease||Intervention/treatment||Phase|
|Functional Dyspepsia||Drug: Itopride (drug)||Phase 2 Phase 3|
Treatment of patients with functional dyspepsia remains unsatisfactory. We will assess the efficacy of Itopride, a D2 antagonist with acetylcholinesterase effects in patients with functional dyspepsia.
Patients with functional dyspepsia will be randomized to Itopride (50, 100 or 200 mg tid) or placebo. After 8 weeks of treatment, three primary efficacy endpoints will be analyzed: a) change of the severity of functional dyspepsia symptoms (assessed by the Leeds Dyspepsia Questionnaire), b) patient’s global assessment of efficacy (proportion of patients symptom-free or markedly improved)and c) improvement of pain and/or fullness by at least one grade on a 5-grade scale.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||500 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Dose Finding Study in 4 Parallel Groups to Establish the Efficacy and Safety of an Eight Week Treatment With Itopride Three Times Daily Compared to Placebo in Patients Suffering From Functional Dyspepsia|
|Study Start Date :||December 2000|
|Study Completion Date :||January 2002|
- After 8 weeks of treatment:
- Change of the severity of functional dyspepsia symptoms assessed by the Leeds Dyspepsia Questionnaire)
- Patient’s global assessment of efficacy (proportion of patients symptom-free or markedly improved)
- Improvement of pain and/or fullness by at least one grade on a 5-grade scale.
- Safety parameters
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00272103
|University Hospital Essen|
|Essen, Germany, 45122|
|Principal Investigator:||Gerald J Holtmann, MD||Royal Adelaide Hospital, University of Adelaide|